Latest news with #RoyalPhilips
Business Upturn
15 hours ago
- Business
- Business Upturn
Philips launches intelligent 3D imaging in Europe to empower faster stroke care, helping physicians save time, brain, and lives
Demonstrated at LINNC Paris 2025, the company's latest release of SmartCT delivers fast, intelligent 3D imaging in the Angio suite — helping physicians act with greater speed and confidence during a range of critical neurovascular procedures Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the CE-marking of its latest SmartCT image reconstruction solution designed to support faster, more informed decision-making in the treatment of stroke and other neurovascular conditions. Already available in Japan and Canada, SmartCT is now CE-marked and available across Europe. The solution will be showcased at LINNC Paris 2025 (June 2–4), the world's leading interventional neuroradiology congress. Built for the Philips Azurion neuro biplane system, the latest generation of SmartCT simplifies and accelerates 3D imaging — giving neuro interventionists real-time views of brain tissue, blood vessels, and interventional devices directly in the Angio suite. By removing the need to transfer patients for separate CT imaging, SmartCT helps care teams treat faster, with greater clarity and confidence. 'In stroke care, minutes matter — and confidence is everything,' said Dr. Atul Gupta, Chief Medical Officer Diagnosis & Treatment at Philips. 'With this latest generation of SmartCT for intelligent 3D imaging applications, we're giving neuro interventionalists the imaging tools they need at the exact moment they need them — improving workflow, reducing delays, and ultimately helping to save lives.' Already used by clinicians at many leading stroke centers worldwide, SmartCT enables a streamlined workflow that reduces procedural complexity and supports timely intervention. This enables physicians to personalize therapy and reduce uncertainty during time-critical procedures like mechanical thrombectomy— a minimally invasive treatment to remove blood clots and restore blood flow to the brain during an ischemic stroke. 'The image quality of the helical cone-beam CT is impressive—it's almost like a conventional CT scan,' said Dr. Shuta Aketa, Director of the Stroke Center at the Osaka International Medical & Science Center. 'This is ideal for emergency procedures, as the image quality meets our needs and helps us work more efficiently.' Dr. Junji Fukumori, Chief of Neurovascular Intervention of the same hospital added 'Compared to other vendors, Philips SmartCT technology allows for more confident and safe treatment of complex cases.' SmartCT 3.0 includes: SmartCT Soft Tissue Helical delivers cone-beam CT (CBCT) imaging in as little as 8 seconds. It offers improved image appearance of cerebral soft tissue volumes by optimizing acquisition trajectory and reconstruction. delivers cone-beam CT (CBCT) imaging in as little as 8 seconds. It offers improved image appearance of cerebral soft tissue volumes by optimizing acquisition trajectory and reconstruction. Motion-compensated soft tissue imaging for restless stroke patients for restless stroke patients SmartCT Dual Phase Cerebral enables clear visualization of vessel occlusions and collateral blood flow in stroke patients, aided by intuitive acquisition guidance and bolus timing tools. enables clear visualization of vessel occlusions and collateral blood flow in stroke patients, aided by intuitive acquisition guidance and bolus timing tools. SmartCT Dual Viewer allows physicians to overlay and manipulate two 3D volumes side-by-side at table side, supporting real-time image fusion and enhanced procedural planning without breaking sterility. At LINNC Paris 2025 (June 2–4, Carrousel du Louvre), Philips will host interactive demos of its latest generation Azurion biplane with SmartCT 3.0 for neuro-endovascular Booth #28. For more information about the Philips Image-Guided Therapy System Azurion, visit our website: For further information, please contact:Joost MalthaPhilips External RelationsTel. : +31 6 10558116 E-mail : [email protected]
Associated Press
7 days ago
- Business
- Associated Press
Philips and March of Dimes Bring Maternal and Pregnancy Health Content to Philips Avent Pregnancy+ App
CAMBRIDGE, Mass. & ARLINGTON, Va.--(BUSINESS WIRE)--May 28, 2025-- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and March of Dimes, the nation's leading nonprofit fighting for the health of all moms and babies, today announced a collaboration aimed at improving maternal health education through the Philips Avent Pregnancy+ app. Philips will integrate essential March of Dimes content into the app to help improve health literacy and create awareness for topics such as preparing for a Neonatal Intensive Care Unit (NICU) stay, preterm birth, and vaccinations. This press release features multimedia. View the full release here: Philips Avent Pregnancy+ app featuring March of Dimes Content The new content will also emphasize the benefits of low dose aspirin, when clinically appropriate, as a preventive treatment for hypertensive disorders of pregnancy, including preeclampsia, aligning with March of Dimes' Low Dose, Big Benefits Campaign. In addition, Philips and March of Dimes will collaborate to identify key research areas, leveraging aggregated app data and surveys to gather valuable insights that will help both organizations further educate and support the needs of mothers and babies. 'Our partnership with Philips reflects our shared commitment to ensuring families have access to trusted, timely information throughout pregnancy,' said Kelly Ernst, Senior Vice President and Chief Impact Officer at March of Dimes. 'Whether it's through our Mom and Baby Mobile Health Centers® or expanding digital health literacy via the Pregnancy+ app, we're meeting families where they are. Initiatives like this represent a meaningful step forward in our mission to improve health outcomes for all moms and babies—and it's partnerships like this that make that progress possible.' Pregnancy+, the world's #1 pregnancy app with more than 80 million lifetime downloads, provides information and guidance throughout a pregnancy including over 800 articles, lifelike 3D baby models, a weekly pregnancy tracker, and audio/video courses led by health and well-being experts. Philips will create awareness campaigns highlighting the new March of Dimes content, including relevant links and assets, that will have broad reach across the United States through the Pregnancy+ app. 'As we continue to seek solutions to address maternal health challenges, initiatives like this can contribute to meaningful change,' said Brenda Kapner, Regional Business Unit Leader, Mother & Childcare, Philips North America. 'By combining our expertise and resources with those of March of Dimes, we aim to deliver accessible education and insights, while utilizing advanced data analysis to better understand and meet the needs of mothers and babies. Together, we have the opportunity to significantly impact maternal and child health outcomes.' About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at About March of Dimes March of Dimes leads the fight for the health of all moms and babies. We support research, education, and advocacy, and provide programs and services so that every family can get the best possible start. Since 1938, we've built a successful legacy to support every pregnant person and every family. Visit or for more information. View source version on CONTACT: Avi Dines Philips North America Tel: +1-781-690-3814 Email:[email protected] KEYWORD: VIRGINIA MASSACHUSETTS EUROPE UNITED STATES NETHERLANDS NORTH AMERICA INDUSTRY KEYWORD: APPS/APPLICATIONS TECHNOLOGY PARENTING CHILDREN BABY/MATERNITY OTHER HEALTH HEALTH CONSUMER GENERAL HEALTH SOURCE: Royal Philips Copyright Business Wire 2025. PUB: 05/28/2025 07:18 AM/DISC: 05/28/2025 07:17 AM
Yahoo
7 days ago
- Business
- Yahoo
Philips and March of Dimes Bring Maternal and Pregnancy Health Content to Philips Avent Pregnancy+ App
Collaboration designed to enhance health awareness for moms during pregnancy and improve health outcomes Aggregated analytics data and surveys from app will help provide maternal health insights CAMBRIDGE, Mass. & ARLINGTON, Va., May 28, 2025--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and March of Dimes, the nation's leading nonprofit fighting for the health of all moms and babies, today announced a collaboration aimed at improving maternal health education through the Philips Avent Pregnancy+ app. Philips will integrate essential March of Dimes content into the app to help improve health literacy and create awareness for topics such as preparing for a Neonatal Intensive Care Unit (NICU) stay, preterm birth, and vaccinations. The new content will also emphasize the benefits of low dose aspirin, when clinically appropriate, as a preventive treatment for hypertensive disorders of pregnancy, including preeclampsia, aligning with March of Dimes' Low Dose, Big Benefits Campaign. In addition, Philips and March of Dimes will collaborate to identify key research areas, leveraging aggregated app data and surveys to gather valuable insights that will help both organizations further educate and support the needs of mothers and babies. "Our partnership with Philips reflects our shared commitment to ensuring families have access to trusted, timely information throughout pregnancy," said Kelly Ernst, Senior Vice President and Chief Impact Officer at March of Dimes. "Whether it's through our Mom and Baby Mobile Health Centers® or expanding digital health literacy via the Pregnancy+ app, we're meeting families where they are. Initiatives like this represent a meaningful step forward in our mission to improve health outcomes for all moms and babies—and it's partnerships like this that make that progress possible." Pregnancy+, the world's #1 pregnancy app with more than 80 million lifetime downloads, provides information and guidance throughout a pregnancy including over 800 articles, lifelike 3D baby models, a weekly pregnancy tracker, and audio/video courses led by health and well-being experts. Philips will create awareness campaigns highlighting the new March of Dimes content, including relevant links and assets, that will have broad reach across the United States through the Pregnancy+ app. "As we continue to seek solutions to address maternal health challenges, initiatives like this can contribute to meaningful change," said Brenda Kapner, Regional Business Unit Leader, Mother & Childcare, Philips North America. "By combining our expertise and resources with those of March of Dimes, we aim to deliver accessible education and insights, while utilizing advanced data analysis to better understand and meet the needs of mothers and babies. Together, we have the opportunity to significantly impact maternal and child health outcomes." About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at About March of Dimes March of Dimes leads the fight for the health of all moms and babies. We support research, education, and advocacy, and provide programs and services so that every family can get the best possible start. Since 1938, we've built a successful legacy to support every pregnant person and every family. Visit or for more information. View source version on Contacts Avi DinesPhilips North AmericaTel: +1-781-690-3814Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
7 days ago
- Health
- Business Wire
Philips and March of Dimes Bring Maternal and Pregnancy Health Content to Philips Avent Pregnancy+ App
CAMBRIDGE, Mass. & ARLINGTON, Va.--(BUSINESS WIRE)-- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and March of Dimes, the nation's leading nonprofit fighting for the health of all moms and babies, today announced a collaboration aimed at improving maternal health education through the Philips Avent Pregnancy+ app. Philips will integrate essential March of Dimes content into the app to help improve health literacy and create awareness for topics such as preparing for a Neonatal Intensive Care Unit (NICU) stay, preterm birth, and vaccinations. The new content will also emphasize the benefits of low dose aspirin, when clinically appropriate, as a preventive treatment for hypertensive disorders of pregnancy, including preeclampsia, aligning with March of Dimes' Low Dose, Big Benefits Campaign. In addition, Philips and March of Dimes will collaborate to identify key research areas, leveraging aggregated app data and surveys to gather valuable insights that will help both organizations further educate and support the needs of mothers and babies. 'Our partnership with Philips reflects our shared commitment to ensuring families have access to trusted, timely information throughout pregnancy,' said Kelly Ernst, Senior Vice President and Chief Impact Officer at March of Dimes. 'Whether it's through our Mom and Baby Mobile Health Centers® or expanding digital health literacy via the Pregnancy+ app, we're meeting families where they are. Initiatives like this represent a meaningful step forward in our mission to improve health outcomes for all moms and babies—and it's partnerships like this that make that progress possible.' Pregnancy+, the world's #1 pregnancy app with more than 80 million lifetime downloads, provides information and guidance throughout a pregnancy including over 800 articles, lifelike 3D baby models, a weekly pregnancy tracker, and audio/video courses led by health and well-being experts. Philips will create awareness campaigns highlighting the new March of Dimes content, including relevant links and assets, that will have broad reach across the United States through the Pregnancy+ app. 'As we continue to seek solutions to address maternal health challenges, initiatives like this can contribute to meaningful change,' said Brenda Kapner, Regional Business Unit Leader, Mother & Childcare, Philips North America. 'By combining our expertise and resources with those of March of Dimes, we aim to deliver accessible education and insights, while utilizing advanced data analysis to better understand and meet the needs of mothers and babies. Together, we have the opportunity to significantly impact maternal and child health outcomes.' About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at About March of Dimes March of Dimes leads the fight for the health of all moms and babies. We support research, education, and advocacy, and provide programs and services so that every family can get the best possible start. Since 1938, we've built a successful legacy to support every pregnant person and every family. Visit or for more information.
Yahoo
20-05-2025
- Health
- Yahoo
Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures
Philips RADIQAL trial May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation 824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark. 'The ability to reduce radiation exposure without compromising procedural performance is a key priority in interventional cardiology,' said Dr. Javier Escaned, Professor of Cardiology at Hospital Clínico San Carlos and principal investigator. 'It is also important to achieve high-quality angiograms when using diluted contrast media as part of ultra-low contrast procedures. RADIQAL is designed to generate robust, real-world evidence on whether Philips' new ultra-low X-ray dose technology can reduce radiation exposure for patients and staff without affecting the quality of coronary procedures.' Coronary artery disease (CAD) is the most frequent type of heart disease affecting millions of people worldwide. It is caused by chronic inflammation of the coronary arteries, which may lead to a gradual obstruction or sudden occlusion of blood flow to the heart muscle. Percutaneous coronary intervention (PCI) is a widely used image-guided, minimally invasive procedure to open blocked coronary arteries and treat CAD. Philips Azurion is an image-guided therapy system which is used for live X-ray imaging during such procedures. The RADIQAL trial evaluates radiation exposure, image quality and procedural performance between Philips' new ultra-low dose technology and existing ClarityIQ technology, both integrated into the Azurion image-guided therapy system. The new technology features an ultra-low dose protocol for coronary procedures, reducing X-ray exposure by 50% compared to even the lowest setting currently available on our Azurion systems with ClarityIQ. This technology has obtained CE marking and as such is cleared under the EU MDR regulatory framework*. 'Reducing radiation exposure while maintaining or improving image-quality is one of the most important innovation goals in interventional cardiology,' said Dr. Darshan Doshi, Head of Medical & Clinical at Philips Image-Guided Therapy Devices and Interventional Cardiologist at the Massachusetts General Hospital in Boston, USA. 'Interventional cardiologists rely on low-dose, high-quality imaging for confident decision-making throughout multiple procedures each day. Also for patients, especially those with high BMI or with complex conditions requiring repeat interventions, minimizing radiation exposure is increasingly critical.' * Not cleared as a medical device in FDA-regulated countries. Enrollment in the US has not started. For further information, please contact: Joost MalthaPhilips Global External Relations Tel.: +31 6 10 55 8116E-Mail: About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at Attachment Philips RADIQAL trial
